Cancer Drug Resistance Reaches New Heights with 2024 Impact Factor of 5.2

June 18, 2025 - Clarivate has officially released the 2024 edition of the Journal Citation Reports (JCR), initiating a new round of global journal evaluations. We are delighted to share that Cancer Drug Resistance (CDR) - the only international journal dedicated exclusively to cancer drug resistance - has reached an inspiring milestone: a 2024 Impact Factor of 5.2, marking a 13% increase from last year’s 4.6!

This notable increase places CDR firmly in thetop quartile (Q1) of the Oncology category, ranking 64th out of 326 journals - a testament to its growing prominence in the global oncology research landscape.

As the sole journal focused on cancer drug resistance, this achievement underscores both CDR’s expanding academic impact and the global scientific community’s strong endorsement of its critical mission: to unravel resistance and accelerate therapeutic progress.

We extend our heartfelt thanks to our Editorial Board, Junior Editorial Board, authors, reviewers, and readers worldwide for their continued trust and contributions. Together, we are making meaningful strides in overcoming one of cancer’s most formidable obstacles.

Editor: Belinda
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance